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S U M M A R Y
Objective: The aim of this study was to determine the level of adherence to Option B+ PMTCT drugs and
factors associated with adherence among HIV-positive pregnant women in public hospitals of Tigray,
northern Ethiopia.
Methods: A cross-sectional study was conducted among 277 HIV-positive pregnant women in 2014. A
two-stage cluster sampling technique was used to select the study participants. Individual consent was
obtained from each participant. Multivariate logistic regression was used to estimate the net effect sizes
of factors associated with adherence to Option B+ PMTCT drugs.
Results: The level of adherence of respondents to Option B+ PMTCT drugs was 87.1% (95% conﬁdence
interval (CI) 82.6–90.7%). Controlling for the effect of other factors, the odds of adhering to Option B+
PMTCT were 4.7 times higher among women who received counselling on medication as compared to
those who did not (adjusted odds ratio (aOR) 4.7, 95% CI 1.98–11.35). Similarly, disclosing HIV status was
positively associated with good adherence (aOR 4.2, 95% CI 1.07–16.33).
Conclusions: The adherence level was found to be reasonably good. Counselling on medication and HIV
status disclosure were positive predictors of adherence to Option B+ PMTCT drugs.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The AIDS epidemic is one of the most destructive epidemics that
the world has ever witnessed.1 Globally, an estimated 35.3 million
adults and 3.2 million children under the age of 15 years were living
with HIV in the year 2012. Sub-Saharan Africa accounts for the
greatest share. With the rising HIV/AIDS prevalence, the number of
children under 5 years of age infected with HIV is increasing.
Mother-to-child transmission (MTCT) of HIV accounts for over 90%
of these cases.2 The risk of HIV transmission from mother to child,
without preventive interventions, ranges from 15% to 40%.3,4
However, in high-income countries, the MTCT rate may be as low
as 1–2%.5Regardless of differences in treatment strategies, the better
outcomes in high-income countries could be explained by the
presence of more robust health systems, greater awareness among
women, accessible information, and higher socioeconomic status
and educational levels compared to limited-resource countries.
According to UNAIDS estimates, 57% of pregnant women living
with HIV in low and middle-income countries received effective* Corresponding author. Tel.: +251914717337.
E-mail address: hafebuy@yahoo.com (H. Ebuy).
http://dx.doi.org/10.1016/j.ijid.2014.12.026
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).antiretroviral (ARV) drugs for the prevention of mother-to-child
transmission (PMTCT) in 2011, a substantial increase from 48% in
2010.6 Nonetheless, many challenges to implementation remain,
chief among which is ensuring that high proportions of women
and children in need of antiretroviral therapy (ART) can access it.7
The World Health Organization (WHO) has started to imple-
ment different strategies for the optimization of PMTCT care and
support: Option A, Option B, and Option B+.7 Under Option A,
women receive antepartum (starting at 14 weeks of gestation) and
intrapartum ARV prophylaxis to reduce the risk of drug resistance.
Under Option B, women receive triple ARVs starting as early as
14 weeks of gestation and this is continued intrapartum and
through childbirth if not breastfeeding, or until 1 week after the
cessation of all breastfeeding. As well as these two options, a third
approach is now being used—Option B+. With this option, all
pregnant women living with HIV are offered life-long ART,
regardless of their CD4 count. Women are administered triple
ARVs starting as soon as diagnosed, continued for life.8
Non-adherence to PMTCT drugs increases the risk of treatment
failure, MTCT, maternal HIV disease progression, and the potential
development of drug-resistant virus.9–11 However, the public
health implications of reduced adherence to Option B and
especially Option B+ in resource-limited settings are not wellious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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tional advantages, and thus could accelerate progress towards
eliminating new paediatric infections. Along with discussing the
potential operational beneﬁts due to the greater simplicity of
Option B and Option B+, the WHO programmatic update also
emphasizes that Option B+ in particular may have signiﬁcant
additional advantages beyond PMTCT; these include providing
better protection for maternal health and a greater reduction in the
sexual transmission of HIV than the other options.8
Preliminary ﬁndings of a routine PMTCT Option B+ programme in
a rural district in Malawi indicated that the lost to follow-up rate was
16.5% at 3 months of follow-up and 21.5% at 6 months of follow-up.13
Reports have also shown that the availability of a limited number of
regimens and the use of ﬁxed dose combinations support
adherence14. It can also limit unnecessary regimen switching and
selective drug taking.15 Moreover, ART preparation at the ﬁrst visit
and the barriers related to the retention and adherence to Option B+
PMTCT need to be fully understood and investigated.
In 2013, the Ethiopian government adopted Option B+ as a
national policy to prevent MTCT of HIV/AIDS.16 However, with
Option B+ PMTCT, there is prolonged exposure to ART, which may
lead to difﬁculties in adhering to treatment for HIV-infected
pregnant women. As such, there is a scarcity of information on
adherence to PMTCT for this new modality in Tigray region.
Furthermore, most studies conducted on adherence to ARV
treatment have focused on the regular patient population with
only a few concentrating on pregnant women and their adherence,
particularly adherence to PMTCT. The aim of this study was to
identify the level of adherence to the Option B+ PMTCT programme
and factors associated with adherence among women on ART in
the Tigray region of northern Ethiopia.
2. Materials and methods
2.1. Study area and setting
A cross-sectional study design was used to assess the level of
adherence and associated factors. The study was done in the public
hospitals of Tigray in the northern part of Ethiopia. The region is
served by 16 hospitals. All of the hospitals provide integrated
maternal, neonatal, and child health (MNCH)/PMTCT services to
HIV-positive women, free of charge. The study recruited pregnant
HIV-positive women who were attending the health institutions
for PMTCT care and support during the study period.Samples  were  allocated  to  each 
hospital  using proporti on- to-
size  all ocati on 
Six hospit als were  selec ted 
rand omly wit h the ass umpti on 
of clus tering 
Women  were  selected  us ing 
simple random sampli ng  from 
each hospital 
Tig
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Figure 1. Schematic presentation2.2. Sampling
A sample of 277 pregnant HIV-positive mothers participated in
the study. The sample size was determined using a single
population proportion with the assumption of a 95% conﬁdence
level, 5% margin of error, and the expected level of adherence to
Option B+ PMTCT of Bwaila Hospital, Malawi (91%).17 To
compensate for non-response, a 10% contingency for the calculated
sample was considered in advance. To decrease the assumed high
variability that might be introduced due to the nature of the cluster
sampling technique, we adjusted the sample size by adopting a
design effect of two.
Two-stage cluster sampling was used to select study partici-
pants.18 Each hospital was considered a cluster. We selected six
hospitals out of 16 using a random sampling method. A speciﬁc
sample size was allocated to each hospital using proportion-to-size
allocation. Thus, we considered 52, 40, 28, 46, 50, and 61 study
participants from Humera, Shire, Axum, Adigrat, Maychew, and
Mekelle hospitals, respectively. Within each hospital, women were
selected at random from the database of women taking PMTCT
drugs (Figure 1). In total, we interviewed 277 women.
Women who were enrolled in the Option B+ PMTCT programme
at the time of the study and who had been on ART for more than
2 months were included in the study. Women who were critically
ill, had been enrolled in PMTCT Option B+ for less than 2 months, or
who had started ART before pregnancy were excluded from the
study.
2.3. Data collection
The data were collected using a questionnaire. The questions
included were based on the Information–Motivation and Beha-
vioural Skills (IMB) model, which was adapted from the Life
Windows Project questionnaire. The IMB is a behavioural model
that postulates that health-related information, motivation, and
behavioural skills are important determinants of whether or not a
health behaviour is performed. If a person is well-informed,
motivated to act, and they have the skills and conﬁdence to take
action, they are more likely to initiate and maintain health-
promoting behaviours that produce positive outcomes.19 A multi-
method tool to measure ART adherence in the resource-con-
strained settings of South Africa and a pharmacy adherence policy
to support adherence to ART were further modiﬁed for Ethiopian
conditions.20 The data were collected using structured interview-
er-administered questionnaires and a document review of theray Pu blic  Healt h Hos pitals  (n = 16)  
Mekelle        
Hospital   
Axum           
Hospital  
Maychew      
Hospital  
        Total  sa mple  size = 277 
Adigrat          
Hospital  
28 46 50 61
 of the sampling procedure.
Table 1
Sociodemographic and economic characteristics of women under Option B+ PMTCT
care and support in public hospitals of Tigray, northern Ethiopia
Variables Number (N = 263) Percentage
Age, years
20–24 40 15.2
25–29 122 46.4
30–34 72 27.4
35–39 29 11.0
Place of residence
Urban 217 82.5
Rural 46 17.5
Religion
Orthodox 241 91.6
Muslim 15 5.7
Catholic 7 2.7
Educational status of the women
No education 128 48.7
Primary (grades 1–8) 61 23.2
Secondary (grades 9–12) 56 21.3
College or beyond 18 6.8
Occupational status of the women
Housewife 112 42.6
Business 45 17.1
Salaried 26 9.9
Daily labourer 53 20.2
Farmer 27 10.3
Household income
<$51.06 41 15.6
$51.07–102.04 150 57
>$102.09 72 27.4
Exposure to radio or TV
Yes 194 73.8
No 69 26.2
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translated back into the local language (Tigrigna) by language
experts to assure the consistency of the questions.
The questionnaire was pre-tested on 14 HIV-positive pregnant
women in Wukro Public Hospital before the actual data collection
to ensure the appropriateness of the content with regard to the
questions, language, and organization. The investigators trained
six clinical nurses (data collectors) and six public health ofﬁcers
(supervisors) for two consecutive days on the objective, data
collection tools, and interview techniques. The interviews were
conducted in a place where the woman could feel free to express
her feelings and ideas. The supervisors checked the questionnaires
for errors and completeness.
2.4. Measurements
The level of adherence was measured using four adherence
measurement questions adapted from the experience in South
Africa, which were designed to measure adherence in the resource-
constrained setting.20 The tool comprises four questions: (1) Do
you sometimes ﬁnd it difﬁcult to remember to take your
medication? (2) When you feel better, do you sometimes take a
break from your medication? (3) Many patients have troubles in
taking their ARV doses as prescribed; did you miss any ARV doses
in the last 3 days? (4) Sometimes if you feel worse when you take
the medicine, do you stop taking it? A woman was considered to
have good adherence if she responded ‘No’ to all four of the
questions. However, if she responded ‘Yes’ to at least one question,
she was considered to have poor adherence.
The knowledge of the women on Option B+ PMTCT was measured
from the total number of correct answers to six knowledge
questions, with a minimum score of 0 and maximum of 6. The
knowledge of the women on the Option B+ PMTCT programme was
considered ‘high’, ‘moderate’, and ‘low’ if they answered 80%, 60–
79%, and <60% of the knowledge questions, respectively.
The attitude of mothers towards the Option B+ PMTCT
programme was deﬁned as ‘positive’ if the score of the attitude
questions was above the median and as ‘negative’ if the score was
below the median.
Regarding male involvement, the composite measure of male
partner involvement in the Option B+ PMTCT programme was
measured from the total number of correct answers to 10 questions
that focus on the male partner’s support of his wife, with a
minimum score of 0 and maximum of 10. Involvement was
considered ‘good’ for those who scored 7, ‘moderate’ for those
who scored 4–6, and ‘low’ for those who scored 3 to the questions
on male partner support.
2.5. Data analysis
The data were analyzed using SPSS 16.0 for windows (SPSS Inc.,
Chicago, IL, USA). Descriptive analyses were carried out to estimate
important indicators. To assess the effect sizes of predictors of
adherence, we analyzed the data using bivariate and multivariate
logistic regression. The effect size of the predictors was depicted
using the crude odds ratio (OR) in the bivariate analysis and
adjusted OR (aOR) in the multivariate analysis, and the population
effect size was estimated using the 95% conﬁdence interval (95%
CI). Necessary model diagnostics and exploratory data analysis
were checked at the respective stages of the analysis. All tests were
considered statistically signiﬁcant at p < 0.05.
2.6. Ethical considerations
Ethical clearance was obtained from the Mekelle University
College of Health Sciences Research and Community ServiceCommittee. Supporting letters were also received from the Tigray
Regional Health Bureau and the district health ofﬁces and
administrative bodies of all hospitals. Informed consent was
obtained from each study participant after an explanation of the
purpose, beneﬁts, and procedures of the study. The right of the
woman to participate and even to withdraw from the study at any
stage was assured. No patient identiﬁers were encoded. The
patient data were kept conﬁdential.
3. Results
3.1. Sociodemographic and economic characteristics of the study
participants
The response rate was 95%; i.e. 14 women did not participate in
the study for different reasons. The median age of the respondents
was 28 years (interquartile range 25–31 years). The majority were
urban residents (82.5%) and Orthodox Christians (91.6%). Four in
10 did not have a job – they were limited to indoor activities.
Regarding educational status, 70 (26.6%) women were illiterate.
Nearly, 74% of the women had access to a radio and 64% to a TV.
Half of the respondents earned a monthly income of $51.07 to
$102.09 (Table 1).
3.2. Clinical characteristics of the study participants
At the start of ART, 70.7% of the respondents were in WHO
clinical stage 1. The majority of respondents started ART (tenofovir,
lamivudine, and efavirenz; TDF–3TC–EFV) immediately after
testing for HIV. Concerning the CD4 count, 122 (46.4%) of the
respondents had a CD4 count of at least 500 cells/mm3. Nearly 64%
of the women had received their ARV medication at PMTCT centres
and the remaining women had received treatment at ART clinics in
areas where there were no separate clinics for PMTCT care and
Table 2
Clinical characteristics by level of adherence among women under Option B+ in
public hospitals of Tigray, northern Ethiopia (N = 263)
Variables Adherence level Chi-square test
Adherent
n (%)
Non-adherent
n (%)
WHO category at admission
Stage 1 167 (89.8)19 (10.2) <0.001
Stage 2 22 (84.6) 4 (15.4)
Stage 3 28 (84.8) 5 (15.2)
Stage 4 12 (66.7) 6 (33.3)
WHO category during the study
Stage 1 (T1) 209 (87.8)29 (12.2) <0.05
Stage 2 (T2) or beyond 20 (80) 5 (20)
CD4 count at admission, cells/mm3
<200 17 (73.9) 6 (26.1) <0.01
200–349 30 (81.1) 7 (18.9)
350–499 74 (91.4) 7 (8.6)
500 108 (88.5)14 (11.5)
Gestational age during the study, weeks
12 71 (91) 7 (9) >0.05
13–28 135 (86.5)21 (13.5)
>28 23 (79.3) 6 (20.7)
Type of PMTCT drug regimen
TDF–3TC–EFV 213 (87.3)31 (12.7) <0.05
Non-TDF–3TC–EFV HAART regimen 16 (84.2) 3 (15.8)
Time to reach health facility (walk)
<1 h 127 (90.1)14 (9.9) >0.05
1 h 102 (83.6)20 (16.4)
Counselled on side effects
Yes 189 (92.2)16 (7.8) <0.01
No 40 (69) 18 (31)
ANC visits
1 35 (83.3) 7 (16.7) <0.05
2 80 (82.5)17 (17.5)
3 66 (86.8)10 (13.2)
4 48 (100) 0 (0)
HIV disclosure to partner
Yes 184 (90.6)19 (9.4) <0.05
No 45 (75) 15 (25)
Receipt of partner support
Yes 175 (92.1)15 (7.9) <0.05
No 54 (74) 19 (26)
WHO, World Health Organization; PMTCT, prevention of mother-to-child
transmission; TDF, tenofovir; 3TC, lamivudine; EFV, efavirenz; HAART, highly
active antiretroviral therapy; ANC, antenatal care.
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dents were counselled on the common side effects of ARV drugs
while they received the drugs. Almost half of the women had
attended antenatal care (ANC) at least three times and 93% of them
had not missed any of the visits. With regard to the length of theAends  AN C with  his  wif e
Remin ds his wife  abou t ANC appoi ntme nt
Discusses th e ad vantage s of  AN C appointm ent
Supports his  wife  ﬁnancial ly to  visit  AN C
Knows th e name of  PMTCT drugs
Knows the  doses  of  PMTCT  drugs
Knows th e frequen cy of  takin g PMTCT drug
Visits PMTCT  clinic with his  wif e to brin g AR V drugs
Discusses with  hi s wife  on use of condom duri ng sex
Shares his wif e decisions  on  hous ehold  issues
Male  involvement  activitie s
Figure 2. Proportions of male involvement activities in Option B+ PMTCT care ajourney to reach the health facilities for PMTCT services, 53.6% of
the women used to walk for less than 1 h (Table 2).
Two hundred three (77.2%) of the respondents had disclosed
their HIV status to their partner. Of these, 61.6% had disclosed their
serostatus before they started PMTCT care and support. The
support from health professionals and mother support groups
played a major role in the woman’s decision to disclose her HIV
status to her male partner. Consequently, 72.2% of the respondents
received support from their partners.
3.3. Male partner involvement, knowledge, and attitude
The composite measure of male involvement in PMTCT services
showed that 111 (42.2%) respondents had ‘low’ male involvement
on PMTCT care and support; 88 (33.5%) and 64 (24.3%) had ‘good’
and ‘moderate’ male involvement, respectively (Figure 2).
The majority of respondents (88.6%) perceived that the HIV-
infected pregnant woman can transmit HIV to her unborn baby. In
addition, they agreed with the statement that it is possible to
reduce the risk of HIV transmission to the baby if the mother takes
PMTCT drugs. More than half of the women (61.6%) were aware
that missing ARV drugs has a negative effect on the prevention of
HIV transmission from mother to child. On the other hand, 87% of
respondents believed that good adherence could reduce the risk of
opportunistic infections (Tables 3 and 4).
In summary, the composite measure of knowledge among HIV-
positive pregnant women showed that 56.7%, 28.1%, and 15.2% had
‘high’, ‘moderate’, and ‘low’ knowledge on Option B+ PMTCT,
respectively.
3.4. Adherence to Option B+ PMTCT drugs
Overall, 87.1% (95% CI 82.6–90.7%) of respondents were
adherent to Option B+ PMTCT drugs. The most frequently
mentioned reason for non-adherence was forgetting when to take
the drugs. This study showed that 34 (12.9%) of the respondents
were non-adherent to Option B+ PMTCT care and support. Out of
these non-adherent respondents, 26 (9.9%) had missed their ARV
medication within the 3 days prior to the study. Among the
challenges for adherence to Option B+ PMTCT, forgetting to take
the medications (92.3%) was the dominant obstacle, followed by
the fear of side effects (38.5%).
3.5. Predictors of adherence to Option B+ PMTCT drugs
The results of the multivariate logistic regression analysis
showed that mothers who were counselled on the correct45.8
82.1
69.5
92.6
50
43.7
54.7
16.8
57.9
71.6
Proportion
nd support among HIV-positive pregnant women in Tigray public hospitals.
Table 3
Knowledge questions and responses regarding Option B+ PMTCT among HIV-positive pregnant mothers in public hospitals of Tigray, northern Ethiopia
Characteristics True False Unsure
n (%) n (%) n (%)
Condom use can prevent HIV transmission during sex with an HIV-infected partner 254 (96.6) 1 (0.4) 8 (3.0)
Seropositive women can transmit HIV to their babies during pregnancy 233 (88.6) 18 (6.8) 12 (4.5)
HIV-positive women can reduce the risk of HIV transmission to their babies if they take PMTCT drugs 221 (84.0) 4 (1.5) 38 (14.5)
Omitting to take some of the PMTCT drugs has no effect on the effectiveness of PMTCT care and support 38 (14.4) 162 (61.6) 63 (24.0)
Adhering to ARV drugs can reduce the risk of opportunistic infections 229 (87.1) 6 (2.3) 28 (10.6)
The support of the male partner during PMTCT care does not have any effect on mothers adhering to PMTCT drugs 64 (34.0) 64 (34.0) 60 (32.0)
PMTCT, prevention of mother-to-child transmission; ARV, antiretroviral.
Table 4
Attitude questions and responses towards Option B+ PMTCT among HIV-positive pregnant mothers in public hospitals of Tigray, northern Ethiopia
Variable Disagree Indifferent Agree
n (%) n (%) n (%)
It is tiresome to take PMTCT drugs every day 174 (66.2) 6 (2.3) 83 (31.6)
Taking PMTCT drugs beneﬁts not only the mother but also the baby 8 (3) 45 (17.1) 210 (79.8)
Starting ART treatment earlier can help to improve quality of life and survival of the mother 10 (3.8) 4 (1.5) 249 (94.7)
Involving the male partner in care and support increases the effectiveness of PMTCT services 50 (19) 48 (18.3) 165 (62.7)
I would not like to give birth taking PMTCT drugs 188 (71.5) 35 (13.3) 40 (15.2)
I do not recommend having sex without a condom regardless of the HIV status of the partner 44 (16.7) 59 (22.4) 160 (60.8)
PMTCT, prevention of mother-to-child transmission; ART, antiretroviral therapy.
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95% CI 1.98–11.35) of adhering to Option B+ PMTCT care and
support as compared to those who were not counselled properly.
Disclosing their HIV status to their partner was also positively
associated with good adherence (aOR 4.2, 95% CI 1.07–16.33)
(Table 5).
4. Discussion
The overall level of adherence to Option B+ PMTCT care and
support was 87.1%. The main predictors affecting adherence for theTable 5
Bivariate and multivariate logistic regression analysis of predictors of adherence to Op
northern Ethiopia
Characteristics Adherence Non- adherence 
n (%) n (%)
Counselled on side effects
Yes 189 (92.2) 16 (7.8) 
No 40 (69) 18 (31) 
HIV status disclosure
Yes 184 (90.6) 19 (9.4) 
No 45 (75) 15 (25) 
WHO clinical stage
Stage 1 or 2 190 (89.2) 23 (10.8) 
Stage 3 or 4 39 (78) 11 (22) 
CD4 count, cells/mm3
350 182 (89.7) 21 (10.3) 
<350 47 (78.3) 13 (21.7) 
Male partner involvement
High 83 (94.3) 5 (5.7) 
Moderate 60 (93.8) 4 (6.2) 
Low 86 (77.5) 25 (22.5) 
Knowledge on Option B+ PMTCT
High 83 (94.3) 5 (5.7) 
Moderate 60 (93.8) 4 (6.2) 
Low 86 (77.5) 25 (22.5) 
Attitude towards Option B+ PMTCT
Positive 190 (90.5) 20 (9.5) 
Negative 39 (73.6) 14 (26.4) 
Place of residence
Urban 192 (88.5) 25 (11.5) 
Rural 37 (80.4) 9 (19.6) 
PMTCT, prevention of mother-to-child transmission; OR, odds ratio; CI, conﬁdence inte
a p < 0.05; bp < 0.01; cp < 0.001. The ﬁndings were also controlled for place of residencwomen included in this study were proper counselling on the
advantages of adhering to the drugs during PMTCT drug provision
and HIV disclosure to their partners.
In this study, 87.1% of the HIV-positive pregnant women were
adherent to Option B+ PMTCT care and support. This percentage is
slightly lower than that reported from a study conducted in Bwaila
Hospital, Malawi (91%).17 The discrepancy in results may be
attributable to the quality of data used for assessing the level of
adherence. In the Malawi study, the researchers used the pill count
from the electronic medical record system; this was not done in
our study and may account for the difference in adherence level.tion B+ PMTCT among HIV-positive pregnant women in public hospitals of Tigray,
Crude OR (95% CI) Adjusted OR (95% CI)
5.31 (2.49–11.30)b 4.75 (1.98–11.35)c
1 1
3.22 (1.52–6.84)b 4.21 (1.07–16.33)a
1 1
2.33 (1.05–5.16)c 1.25 (0.35–4.52)
1 1
2.39 (1.11–5.13)b 2.28 (0.67–7.71)
1 1
4.82 (1.76–13.20)a 2.01 (0.49–8.19)
4.36 (1.44–13.17)a 3.34 (0.78–14.18)
1 1
1 1
0.45 (0.19–1.06) 0.75 (0.27–2.09)
0.26 (0.10–0.66)b 0.37 (0.12–1.16)
3.4 (1.58–7.32)a 2.03 (0.80–5.15)
1 1
1.4 (0.8–14.2) 2.3 (0.4–10.6)
1 1
rval; WHO, World Health Organization.
e, prior PMTCT experiences, TV possession, and the time to reach the health facility.
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Saharan Africa, the adherence level in our study is slightly higher
than those reported from Nnewi in Nigeria (78.3%), Lagos in
Nigeria (80.6%), and Kisumu in Kenya (82%), but lower than that
reported from western Kenya (89%).21–24 This may reﬂect
differences in the PMTCT option used, as most of these studies
focused on Option A PMTCT; Option A is a different strategy for
PMTCT care and support to Option B+. This difference could have
had an effect on the adherence level, as the latter may be
considered a simpliﬁed option. However, our ﬁnding shows a
lower adherence level as compared to that reported in a study
carried out in Addis Ababa, Ethiopia. This discrepancy may have
resulted from differences in awareness, educational level of the
women, and better access to infrastructure in Addis Ababa than in
the current study area.25
Studies done in Nnewi in Nigeria, Lagos in Nigeria, and Ghana
show that 88.3%, 86.5%, and 85.5%, respectively, of women had
disclosed their HIV status to their partner. Statistically, disclosure
status was signiﬁcantly associated with adherence to Option B+
PMTCT care and support.21,22,26 These percentages are slightly
higher compared to ours (77.2%). However, they are consistent
with those of studies done in Addis Ababa and Tanzania.27,28
Disclosure of HIV status to their partner, the partner’s involvement
in HIV testing, and counselling on ARV drugs had no signiﬁcant
association with adherence in the study done in Addis Ababa.29
Generally, HIV status disclosure is considered important in
diminishing the transmission of HIV infection in HIV-negative
male sexual partners (discordant couple), which is one of the
additional beneﬁts of Option B+ over options A and B.8,12 This
ﬁnding implies that stakeholders should also focus on male
partners to optimize the beneﬁts of Option B+ PMTCT care and
support.
Proper counselling on the side effects of ARV drugs was found to
be a signiﬁcant predictor of better adherence to Option B+ PMTCT,
even though there are no other studies showing this relationship.
This association is plausible since women experiencing side effects
of the ARV drugs are less likely to trust the treatment and adhere to
it.30 Another study showed that women experiencing milder side
effects such as skin rash or skin discolorations, fatigue, headache,
and fever were more likely to adhere to Option B+ PMTCT drugs
than those experiencing more severe side effects such as metabolic
effects (central nervous system (CNS) toxicity, severe hepatic
necrosis, and renal toxicity).31 This is consistent with our study, in
which the study participants who were counselled about their
medication were more likely to adhere to Option B+ PMTCT care
and support. This appears plausible since one of the drug regimens
of Option B+ (TDF–3TC–EFV) has the potential to induce side
effects of CNS toxicity like headache, strange dreams, and
confusion; this is particularly due to efavirenz. The missed
opportunity to counsel on the potential side effects of this regimen
may have a negative impact on the mother’s satisfaction with the
medication.
A study conducted in Ghana showed that the majority of
respondents (92.2%) perceived that MTCT of HIV/AIDS was possible
and that 88.3% of the respondents were aware that it was possible
to reduce the risk of infection in the baby if they took PMTCT drugs
effectively.26 This is in agreement with our ﬁndings.
A number of participants in the studies carried out in Nnewi,
Nigeria (63.8%), Lagos, Nigeria (57.6%), and Addis Ababa health
centres (20.8%) showed that the main reason reported by the non-
adherent respondents for missing their drugs was forgetful-
ness.21,22,25 Our study also showed a similar ﬁnding – forgetting
when to take the ARV drugs was the most frequently mentioned
reason for non-adherence (92.3%).
There are limitations to this study. Option B+ continues life-
long and it lacks tracing of the change in adherence over the courseof treatment, including in the postpartum period. Furthermore,
adherence was evaluated based on self-report, thus the adherence
estimate might be affected by some recall bias. However, we
believe that the study complemented the weaknesses with
methodological strengths and that the ﬁndings are not affected
much by the possible limitations.
In conclusion, the level of adherence of HIV-positive pregnant
respondents to Option B+ PMTCT drugs was 87%. The main
predictors affecting adherence were proper counselling on the
advantages of PMTCT drugs, care and support, and HIV disclosure
to partners.
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